06.05.2025 • News

MSSA Doubles Production Capacity for Sodium Methylate

MSSA, part of the International Chemical Investors Group (ICIG), announced the expansion of its sodium methylate production unit at its La Rochelle, France, site.

The sodium methylate unite in La Rochelle.
The sodium methylate unite in La Rochelle.
© MSSA

The strategic investment will double MSSA‘s annual production capacity for sodium methylate from 20,000 t to 40,000 t, reinforcing the company‘s commitment to meeting the growing demand for sodium methylate from mercury-free processes. 

As part of the expansion project, a second production line will be added to MSSA’s sodium methylate production plant in La Rochelle, France, which it operates in a joint venture with SISP, an affiliate of port logistics service provider Groupe Sica Atlantique. The new production line will use the same mercury-free sodium metal-based production process as the existing line. 

Construction works will start by mid-2025 and the new production line is expected to be operational by mid-2026. The project represents an investment of several million euros and will further strengthen employment at MSSA’s La Rochelle site. MSSA operates another production facility in Pomblière, France. Sodium methylate is primarily used as a catalyst in the production of biodiesel, as well as in fine chemicals and pharmaceuticals applications.

Dimitri Rimbert, President and CEO of MSSA commented: "This significant expansion of our sodium methylate production unit underscores our dedication to providing our customers with sodium methylate from mercury-free processes produced in Europe. The increased capactiy will enable us to better serve our existing customers, capture new market opportunities, and strengthen our activities in La Rochelle."

Company

ICIG



Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.